SynthesisBMC public health2022
The impact of clinical and population strategies on coronary heart disease mortality: an assessment of Rose's big idea.
Synthesis in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Occupational Risk for Coronary Artery Disease in Shift Workers - A Systematic Review.La Medicina del lavoro · 2024Pooled it
- Premature coronary artery disease in women: sex-specific risk factors, pathogenetic mechanisms and clinical implications.Annals of medicine · 2026Review
- Article
- Cardiovascular Risk and Modifiable Risk Factors in Shift-Working Healthcare Workers: A Gender-Stratified Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Targeting cardiomyocyte-derived extracellular vesicle miR-574-5p protects against cognitive impairment induced by ischemia-reperfusion.BMC medicine · 2026Article
- Temporal trends and projected mortality of myocardial infarction and heart failure in the United States, 1999-2035: a CDC WONDER analysis.Frontiers in cardiovascular medicine · 2026Article
- Temporal trends in mortality due to coronary heart disease in Germany from 1998 to 2023.Journal of health monitoring · 2025Article
- [Cause of death statistics-how to avoid misinterpretation of mortality data].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- Going from Primary to Primordial Prevention: Is the Juice Worth the Squeeze?Current cardiology reports · 2024Review
- Antioxidant and cholesterol regulatory effect of flavonoid-rich silk sericin.Food science and biotechnology · 2024Article
- Environmental Pollution and Cardiovascular Disease: Part 1 of 2: Air Pollution.JACC. Advances · 2024Review
- Age- And Gender-Based Predisposition Of MMP-9 -1562 C > T Genotype And Allele Frequencies With Serum MMP-9 Levels As Probable Risk Factors In Patients With Coronary Artery Disease.Indian journal of clinical biochemistry : IJCB · 2023Article
- Malaysian burden of disease: years of life lost due to premature deaths.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary heart disease (CHD), the leading cause of death worldwide, has declined in many affluent countries but it continues to rise in industrializing countries.
objectiveTo quantify the relative contribution of the clinical and population strategies to the decline in CHD mortality in affluent countries.
designMeta-analysis of cross-sectional and prospective studies. DATA SOURCES: PubMed and Web of Science from January 1, 1970 to December 31, 2019.
methodWe combined and analyzed data from 22 cross-sectional and prospective studies, representing 500 million people, to quantify the relative decline in CHD mortality attributable to the clinical strategy and population strategy.
resultThe population strategy accounted for 48% (range = 19 to 73%) of the decline in CHD deaths and the clinical strategy accounted for 42% (range = 25 to 56%), with moderate inconsistency of results across studies.
conclusionSince 1970, a larger fraction of the decline in CHD deaths in industrialized countries was attributable to reduction in CHD risk factors than medical care. Population strategies, which are more cost-effective than clinical strategies, are under-utilized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.